The market is estimated to grow with a CAGR of 6. 2% from 2019-2027. The market for nuclear medicine/radiopharmaceuticals is expected to grow, owing to factors such as rising prevalence of chronic diseases, alpha radioimmunotherapy-based targeted oncology treatment and advancement in imaging technologies using radiopharmaceuticals play vital role in the growth of the radiopharmaceuticals market.
New York, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Nuclear Medicine/Radiopharmaceuticals Market to 2027 - Global Analysis and Forecasts by Applications; End User and Geography" - https://www.reportlinker.com/p05794741/?utm_source=GNW
However, the restraints such as short shelf-life of radiopharmaceuticals and availability of substitutes of radiopharmaceuticals are likely to impact the growth of the market in the forecast period.
A radiopharmaceutical is a drug, which can be used either for diagnostic or therapeutic purposes.Radiopharmaceuticals are radioisotopes that are bound to biological molecules that target specific tissues, organs, or cells within the human body.
Radioisotopes emitting gamma rays are useful for diagnostic imaging where the radiation escapes the body. These rays are detected by a specific device, which is usually single-photon emission computed tomography (SPECT)/ positron emission tomography (PET) cameras.
The shelf-life or expiry date of a radiopharmaceutical preparation depends mainly on the half-life of the radioisotope, the radiochemical stability and the content of longer-lived radionuclide impurities in the preparation under consideration.Most of the radiopharmaceutical preparations contain radioisotopes with very short half-lives and such preparations have very short shelf-lives.
These preparations require an expiry date and time to be indicated.For example, technetium based preparations and positron emission tomography (PET) preparations are generally intended to be used within less than 12 hours, or sometimes within few minutes of preparation.
Hence, the short shelf-life of radiopharmaceuticals are expected to hinder the growth of the market in the future years.
Global nuclear medicine/radiopharmaceuticals were segmented by application and end user.The application segment was segmented as diagnostic applications and therapeutic applications.
Based on the end user, the market was segmented as hospitals and diagnostic centers. During 2018, the hospitals segment led the nuclear medicine/radiopharmaceuticals market by the end user.
Some of the major primary and secondary sources included in the report for, Society of Nuclear Medicine, Food and Drug Administration, American Cancer Society, World Health Organization, American Hospital Association (AHA), National Cancer Institute (NCI), Canadian Association of Nuclear Medicine, and others.
Read the full report: https://www.reportlinker.com/p05794741/?utm_source=GNW
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001